Conditions: Carcinoma, Renal Cell; Head and Neck Neoplasm; Skin Neoplasms; Microsatellite Instability; Penile Neoplasms
Intervention: Drug: Nivolumab
Sponsors: UNICANCER; National Cancer Institute, France; Ligue contre le cancer, France; Bristol-Myers Squibb
Not yet recruiting - verified January 2017
AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol - Introduction Sepsis is a leading global cause of morbidity and mortality, and is more common at the extremes of age. Moreover, the cost of in-hospital car...